Roper Technologies
ROPER TECHNOLOGIES, INC.
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$7.9B
Operating marginCalculated
28.3%
Net assets to total assetsCalculated
57.5%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★★★position among all companies
28.3%
Growth (revenue, 4-year average)
★★★★☆position among all companies
13.1%
Capital efficiency
★★☆☆☆position among all companies
7.7%
Revenue and profit
Performance, financial position and capital allocation
Roper Technologies
Recent performance trends
Roper Technologies
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$4.8 billion | US$5.4 billion | US$6.2 billion | US$7.0 billion | US$7.9 billion |
| Operating income | US$1.2 billion | US$1.5 billion | US$1.7 billion | US$2.0 billion | US$2.2 billion |
| Net income | US$1.2 billion | US$4.5 billion | US$1.4 billion | US$1.5 billion | US$1.5 billion |
| Total assets | US$23.7 billion | US$27.0 billion | US$28.2 billion | US$31.3 billion | US$34.6 billion |
| Shareholders' equity | US$11.6 billion | US$16.0 billion | US$17.4 billion | US$18.9 billion | US$19.9 billion |
| Net cash provided by (used in) operating activities | US$2.0 billion | US$0.7 billion | US$2.0 billion | US$2.4 billion | US$2.5 billion |
| Net cash provided by (used in) investing activities | US$-0.1 billion | US$1.2 billion | US$-2.1 billion | US$-3.5 billion | US$-3.4 billion |
| Net cash provided by (used in) financing activities | US$-1.8 billion | US$-1.5 billion | US$-0.5 billion | US$1.1 billion | US$0.9 billion |
| Cash and cash equivalents | US$0.4 billion | US$0.8 billion | US$0.2 billion | US$0.2 billion | US$0.3 billion |
Revenue scale in the same industry
Roper Technologies
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- … 12 companies
- 16 SolventumFY Dec 2025 US$8.3B
- 17 Zimmer Biomet HoldingsFY Dec 2025 US$8.2B
- 18 Roper TechnologiesThis companyFY Dec 2025 US$7.9B
- 19 AmetekFY Dec 2025 US$7.4B
- 20 GarminFY Dec 2025 US$7.2B
- … 23 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Cash and cash equivalents | US$0.3 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$0.9 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-3.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$2.5 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.9 billion | Consolidated | Disclosed |
| Dividends paid | US$0.4 billion | Consolidated | Disclosed |
| Net assets | US$19.9 billion | Consolidated | Disclosed |
| Net sales | US$7.9 billion | Consolidated | Disclosed |
| Operating income | US$2.2 billion | Consolidated | Disclosed |
| Net income | US$1.5 billion | Consolidated | Disclosed |
| Total assets | US$34.6 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$0.5 billion | Consolidated | Disclosed |
| Operating margin | 28.3% | Consolidated | Calculated |
| Net assets to total assets | 57.5% | Consolidated | Calculated |
| Net margin | 19.4% | Consolidated | Calculated |
| Return on equity | 7.7% | Consolidated | Calculated |